The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Sterling takes hit as euro zone countries suspend AstraZeneca vaccine

Tue, 16th Mar 2021 11:42

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv
(Adds chart, quote; updates background and rates)

By Joice Alves

LONDON, March 16 (Reuters) - Sterling fell against both the
euro and the dollar on Tuesday with analysts attributing the
move to news that Germany, Italy and France suspended
AstraZeneca's COVID-19 shots amid safety fears,
dampening euphoria in Britain over its swift vaccination push.

Sterling fell 0.3% versus the dollar to $1.3853 at 1118 GMT,
after hitting a one-week low of $1.3809 in earlier trading
. Against the euro, it was 0.4% lower at 86.21 pence,
having touched at 0926 GMT its lowest level of 86.40 pence since
March 5.

The euro zone countries said they would suspend the
AstraZeneca shots after several other European countries
reported possible serious side-effects, but the World Health
Organization said there was no proven link and people should not
panic. Shares in the British vaccine maker were up 3% on
Tuesday.

Britain said it had no concerns, but analysts have been
cautious saying that if the safety fears surrounding AstraZeneca
vaccine are confirmed, this could compromise Britain's speedy
inoculation programme.

"Should the EMA (European Medicines Agency) rule that
AstraZeneca does indeed have material safety concerns, this
would potentially compromise the UK vaccine strategy, even if
the EMA no longer have any standing in the UK post Brexit," said
Jeremy Stretch, head of G10 FX Strategy at CIBC Capital Markets.

Such an outcome would risk sterling falling to around
$1.3798, Stretch said.

The EMA will hold a news conference at 1300 GMT on Tuesday.

Sterling gained more than 5% against the dollar in the first
seven weeks of the year amid hopes for a relatively fast
economic recovery following a speedy vaccination programme and
declining numbers of COVID-19 cases in Britain.

Dwindling expectations that the BoE will push interest rates
below zero, and the Brexit trade deal with the EU agreed in
December, have also supported the pound, which rose above $1.42
on February 24.

But over the past two weeks, cable fell 3% amid rising
tension between Britain and the bloc, as well as a recent surge
in Treasury yields, which strengthened the dollar and added
pressure on risk currencies like sterling.

The European Union launched on Monday legal action against
unilateral British changes to Northern Irish trading
arrangements.

"The negative news flow about the Oxford vaccine in the EU
and the coincident news about legal action by the EU against the
UK has been sufficient to knock confidence in the pound," said
Jane Foley, head of FX Strategy at Rabobank.

Markets will be looking to the BoE’s announcement on
Thursday, analysts said.

(Reporting by Joice Alves; editing by Emelia Sithole-Matarise
and Ed Osmond)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.